Therapeutic implications of treatment with cefonicid on airway reactivity during bacterial lower respiratory tract infections

M. Cazzola, R. De Palma, N. Maurea, A. Mascitelli, P. Martucci, G. D'Amato

Research output: Contribution to journalArticle

Abstract

Airway hyperreactivity may contribute to acute, transient exacerbation experienced by patients with chronic obstructive pulmonary disease (COPD). It is well established that airway infections result in increased bronchospasm in response to inhaled methacholine and histamine. It is also known that gram-negative bacteria induce the release of histamine and deterioration of the pulmonary beta-adrenergic system in order to contribute to bronchial hyperreactivity in patients with COPD. The purpose of this study was to determine whether cefonicid, a long-acting cephalosporin that is active at low concentrations against Haemophilus influenzae and Streptococcus pneumoniae (the most frequently encountered causal bacteria in COPD), was able to block or reduce acute bronchospasm triggered by methacholine in 20 patients, ten affected with H influenzae-related infection and ten affected with S pneumoniae-related infection. After a seven-day course of treatment with cefonicid, the rate of bronchial hyperreactivity to methacholine, expressed as the provocative dose producing a 15% (PD15) fall in forced expiratory volume of the first second (FEV1)was changed: cefonicid significantly decreased the airway response to methacholine (the mean PD15 FEV1 was enhanced). The PD15 FEV1 rise after cefonicid was more accentuated (+9.4% vs +7.7%) in patients with H influenzae infection. Our data show that an antibiotic of proven efficacy must be indicated in the treatment of lower respiratory tract infection in patients with COPD where a gram-negative bacterium is suspected as a pathogen. Also, it is indicated because of its therapeutic implications on bronchial hyperreactivity.

Original languageEnglish
Pages (from-to)559-567
Number of pages9
JournalCurrent Therapeutic Research
Volume45
Issue number4
Publication statusPublished - 1989

Fingerprint

Cefonicid
Respiratory Tract Infections
Methacholine Chloride
Bronchial Hyperreactivity
Chronic Obstructive Pulmonary Disease
Bronchial Spasm
Infection
Gram-Negative Bacteria
Human Influenza
Therapeutics
Histamine Release
Haemophilus influenzae
Forced Expiratory Volume
Cephalosporins
Streptococcus pneumoniae
Adrenergic Agents
Histamine
Pneumonia
Anti-Bacterial Agents
Bacteria

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Therapeutic implications of treatment with cefonicid on airway reactivity during bacterial lower respiratory tract infections. / Cazzola, M.; De Palma, R.; Maurea, N.; Mascitelli, A.; Martucci, P.; D'Amato, G.

In: Current Therapeutic Research, Vol. 45, No. 4, 1989, p. 559-567.

Research output: Contribution to journalArticle

Cazzola, M. ; De Palma, R. ; Maurea, N. ; Mascitelli, A. ; Martucci, P. ; D'Amato, G. / Therapeutic implications of treatment with cefonicid on airway reactivity during bacterial lower respiratory tract infections. In: Current Therapeutic Research. 1989 ; Vol. 45, No. 4. pp. 559-567.
@article{1213003802fb4acdb6a2a5d3d816794b,
title = "Therapeutic implications of treatment with cefonicid on airway reactivity during bacterial lower respiratory tract infections",
abstract = "Airway hyperreactivity may contribute to acute, transient exacerbation experienced by patients with chronic obstructive pulmonary disease (COPD). It is well established that airway infections result in increased bronchospasm in response to inhaled methacholine and histamine. It is also known that gram-negative bacteria induce the release of histamine and deterioration of the pulmonary beta-adrenergic system in order to contribute to bronchial hyperreactivity in patients with COPD. The purpose of this study was to determine whether cefonicid, a long-acting cephalosporin that is active at low concentrations against Haemophilus influenzae and Streptococcus pneumoniae (the most frequently encountered causal bacteria in COPD), was able to block or reduce acute bronchospasm triggered by methacholine in 20 patients, ten affected with H influenzae-related infection and ten affected with S pneumoniae-related infection. After a seven-day course of treatment with cefonicid, the rate of bronchial hyperreactivity to methacholine, expressed as the provocative dose producing a 15{\%} (PD15) fall in forced expiratory volume of the first second (FEV1)was changed: cefonicid significantly decreased the airway response to methacholine (the mean PD15 FEV1 was enhanced). The PD15 FEV1 rise after cefonicid was more accentuated (+9.4{\%} vs +7.7{\%}) in patients with H influenzae infection. Our data show that an antibiotic of proven efficacy must be indicated in the treatment of lower respiratory tract infection in patients with COPD where a gram-negative bacterium is suspected as a pathogen. Also, it is indicated because of its therapeutic implications on bronchial hyperreactivity.",
author = "M. Cazzola and {De Palma}, R. and N. Maurea and A. Mascitelli and P. Martucci and G. D'Amato",
year = "1989",
language = "English",
volume = "45",
pages = "559--567",
journal = "Current Therapeutic Research - Clinical and Experimental",
issn = "0011-393X",
publisher = "Excerpta Medica",
number = "4",

}

TY - JOUR

T1 - Therapeutic implications of treatment with cefonicid on airway reactivity during bacterial lower respiratory tract infections

AU - Cazzola, M.

AU - De Palma, R.

AU - Maurea, N.

AU - Mascitelli, A.

AU - Martucci, P.

AU - D'Amato, G.

PY - 1989

Y1 - 1989

N2 - Airway hyperreactivity may contribute to acute, transient exacerbation experienced by patients with chronic obstructive pulmonary disease (COPD). It is well established that airway infections result in increased bronchospasm in response to inhaled methacholine and histamine. It is also known that gram-negative bacteria induce the release of histamine and deterioration of the pulmonary beta-adrenergic system in order to contribute to bronchial hyperreactivity in patients with COPD. The purpose of this study was to determine whether cefonicid, a long-acting cephalosporin that is active at low concentrations against Haemophilus influenzae and Streptococcus pneumoniae (the most frequently encountered causal bacteria in COPD), was able to block or reduce acute bronchospasm triggered by methacholine in 20 patients, ten affected with H influenzae-related infection and ten affected with S pneumoniae-related infection. After a seven-day course of treatment with cefonicid, the rate of bronchial hyperreactivity to methacholine, expressed as the provocative dose producing a 15% (PD15) fall in forced expiratory volume of the first second (FEV1)was changed: cefonicid significantly decreased the airway response to methacholine (the mean PD15 FEV1 was enhanced). The PD15 FEV1 rise after cefonicid was more accentuated (+9.4% vs +7.7%) in patients with H influenzae infection. Our data show that an antibiotic of proven efficacy must be indicated in the treatment of lower respiratory tract infection in patients with COPD where a gram-negative bacterium is suspected as a pathogen. Also, it is indicated because of its therapeutic implications on bronchial hyperreactivity.

AB - Airway hyperreactivity may contribute to acute, transient exacerbation experienced by patients with chronic obstructive pulmonary disease (COPD). It is well established that airway infections result in increased bronchospasm in response to inhaled methacholine and histamine. It is also known that gram-negative bacteria induce the release of histamine and deterioration of the pulmonary beta-adrenergic system in order to contribute to bronchial hyperreactivity in patients with COPD. The purpose of this study was to determine whether cefonicid, a long-acting cephalosporin that is active at low concentrations against Haemophilus influenzae and Streptococcus pneumoniae (the most frequently encountered causal bacteria in COPD), was able to block or reduce acute bronchospasm triggered by methacholine in 20 patients, ten affected with H influenzae-related infection and ten affected with S pneumoniae-related infection. After a seven-day course of treatment with cefonicid, the rate of bronchial hyperreactivity to methacholine, expressed as the provocative dose producing a 15% (PD15) fall in forced expiratory volume of the first second (FEV1)was changed: cefonicid significantly decreased the airway response to methacholine (the mean PD15 FEV1 was enhanced). The PD15 FEV1 rise after cefonicid was more accentuated (+9.4% vs +7.7%) in patients with H influenzae infection. Our data show that an antibiotic of proven efficacy must be indicated in the treatment of lower respiratory tract infection in patients with COPD where a gram-negative bacterium is suspected as a pathogen. Also, it is indicated because of its therapeutic implications on bronchial hyperreactivity.

UR - http://www.scopus.com/inward/record.url?scp=0024524110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024524110&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0024524110

VL - 45

SP - 559

EP - 567

JO - Current Therapeutic Research - Clinical and Experimental

JF - Current Therapeutic Research - Clinical and Experimental

SN - 0011-393X

IS - 4

ER -